JP2017506075A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506075A5
JP2017506075A5 JP2016550540A JP2016550540A JP2017506075A5 JP 2017506075 A5 JP2017506075 A5 JP 2017506075A5 JP 2016550540 A JP2016550540 A JP 2016550540A JP 2016550540 A JP2016550540 A JP 2016550540A JP 2017506075 A5 JP2017506075 A5 JP 2017506075A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
igg class
protein according
class antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/052119 external-priority patent/WO2015117930A1/en
Publication of JP2017506075A publication Critical patent/JP2017506075A/ja
Publication of JP2017506075A5 publication Critical patent/JP2017506075A5/ja
Pending legal-status Critical Current

Links

JP2016550540A 2014-02-06 2015-02-03 インターロイキン−１０イムノコンジュゲート Pending JP2017506075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936642P 2014-02-06 2014-02-06
US61/936,642 2014-02-06
PCT/EP2015/052119 WO2015117930A1 (en) 2014-02-06 2015-02-03 Interleukine 10 immunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000462A Division JP2020089371A (ja) 2014-02-06 2020-01-06 インターロイキン−１０イムノコンジュゲート

Publications (2)

Publication Number Publication Date
JP2017506075A JP2017506075A (ja) 2017-03-02
JP2017506075A5 true JP2017506075A5 (https=) 2018-03-15

Family

ID=52440687

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016550540A Pending JP2017506075A (ja) 2014-02-06 2015-02-03 インターロイキン−１０イムノコンジュゲート
JP2020000462A Withdrawn JP2020089371A (ja) 2014-02-06 2020-01-06 インターロイキン−１０イムノコンジュゲート
JP2022040084A Pending JP2022095643A (ja) 2014-02-06 2022-03-15 インターロイキン－１０イムノコンジュゲート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020000462A Withdrawn JP2020089371A (ja) 2014-02-06 2020-01-06 インターロイキン−１０イムノコンジュゲート
JP2022040084A Pending JP2022095643A (ja) 2014-02-06 2022-03-15 インターロイキン－１０イムノコンジュゲート

Country Status (12)

Country Link
US (1) US20150218244A1 (https=)
EP (1) EP3102594A1 (https=)
JP (3) JP2017506075A (https=)
KR (1) KR20160117463A (https=)
CN (1) CN106061997A (https=)
AR (1) AR099288A1 (https=)
BR (1) BR112016016658A2 (https=)
CA (1) CA2935665A1 (https=)
MX (1) MX2016010174A (https=)
RU (1) RU2016135788A (https=)
TW (1) TW201613954A (https=)
WO (1) WO2015117930A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
EP3973980A1 (en) 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
RU2018124307A (ru) * 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
CN108948207B (zh) * 2017-05-22 2020-11-13 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
JP7710706B2 (ja) 2017-09-25 2025-07-22 シーフイダ ファーマシューティカル グループ （チーリン） カンパニー リミテッド 癌治療のための方法及び組成物
US20200353050A1 (en) * 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
WO2020037043A1 (en) 2018-08-15 2020-02-20 The Regents Of The University Of California Il-10 inhibition for vaccines and immunotherapy
CN112654641A (zh) * 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
JP2022512746A (ja) * 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
WO2020097946A1 (zh) * 2018-11-18 2020-05-22 杭州博虎生物科技有限公司 一种重组人白细胞介素10融合蛋白及其应用
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
CN121652287A (zh) * 2019-03-06 2026-03-13 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
WO2020229378A1 (en) * 2019-05-13 2020-11-19 F. Hoffmann-La Roche Ag Interference-suppressed pharmacokinetic immunoassay
CN114599390A (zh) * 2019-06-10 2022-06-07 浙江冠科美博生物科技有限公司 抗体-白介素融合蛋白以及使用方法
JP2022540187A (ja) * 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド 新規融合タンパク質及びその用途
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
EP4087947A4 (en) * 2020-01-09 2024-05-01 Deka Biosciences, Inc. METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT
EP4093875A4 (en) * 2020-01-20 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Ligand-binding fusion proteins
WO2021231447A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
WO2021230460A1 (ko) * 2020-05-14 2021-11-18 주식회사 제넥신 Pd-l1 단백질 및 단량체성 il-10 변이체가 포함된 융합 단백질 및 이의 용도
CA3180304A1 (en) * 2020-05-28 2021-12-02 Kenan Christopher GARCIA Engineered interleukin-10 polypeptides and uses thereof
PE20231082A1 (es) * 2020-06-26 2023-07-17 Amgen Inc Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CA3204723A1 (en) * 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
KR20230129983A (ko) * 2020-12-09 2023-09-11 애셔 바이오테라퓨틱스, 인크. 조작된 세포 요법을 위한 표적화된 사이토카인 구축물
IL303501A (en) * 2020-12-10 2023-08-01 Biocad Joint Stock Co Immunogenic cytokine for activation of the human IL-10RA receptor and its use
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
US20240190934A1 (en) * 2022-11-28 2024-06-13 Elixiron Immunotherapeutics (hong Kong) Limited Engineered interleukin-10 and fusion proteins thereof
CN118240058A (zh) * 2022-12-24 2024-06-25 广东菲鹏制药股份有限公司 Il10突变体、融合蛋白和药物
EP4647489A1 (en) * 2023-01-03 2025-11-12 Shenzhen Synthetica Pioneering Co., Ltd. Bacteria secreting interleukin-10
EP4719457A2 (en) * 2023-06-02 2026-04-08 Synthekine, Inc. Fused il10 polypeptides
TW202540200A (zh) * 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN121343001A (zh) * 2024-07-16 2026-01-16 广东菲鹏制药股份有限公司 一种融合蛋白及其用途
CN119331091B (zh) * 2024-11-06 2025-05-13 重庆探生科技有限公司 一种抗人白介素6的单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
CA2648484A1 (en) * 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
DK3281952T3 (da) * 2007-10-30 2020-08-03 Philogen Spa Antigen, der er forbundet med reumatoid artritis
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins
NO2344540T3 (https=) * 2008-10-02 2018-04-28
CA2806021C (en) * 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas

Similar Documents

Publication Publication Date Title
JP2017506075A5 (https=)
RU2016135788A (ru) Иммуноконъюгаты интерлейкина 10
JP2015530983A5 (https=)
US20240067757A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US11834495B2 (en) Modified-IgG antibodies that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
US20170226214A1 (en) Antibodies against g-csfr and uses thereof
CN115397852B (zh) 工程化抗il-2抗体
US20240343790A1 (en) Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity
AU2014226093A1 (en) Anti-TNF-anti-IL-17 bispecific antibodies
US20220227867A1 (en) ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
US20240010695A1 (en) Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
RU2019123112A (ru) Анти-il-5 антитела
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
WO2022192586A1 (en) Heterodimeric antibodies that bind cd3 and gpc3
CN115151567A (zh) 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化
CN116829577A (zh) 用于调节免疫细胞功能的突变型白介素-10多肽与抗原结合分子的融合物
CA2978459C (en) Scfv-fc dimers that bind transforming growth factor-.beta.1 with high affinity, avidity and specificity
CA2978439C (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40119111A (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40117203A (en) Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity